Cargando…

VEGF controls lung Th2 inflammation via the miR-1–Mpl (myeloproliferative leukemia virus oncogene)–P-selectin axis

Asthma, the prototypic Th2-mediated inflammatory disorder of the lung, is an emergent disease worldwide. Vascular endothelial growth factor (VEGF) is a critical regulator of pulmonary Th2 inflammation, but the underlying mechanism and the roles of microRNAs (miRNAs) in this process have not been def...

Descripción completa

Detalles Bibliográficos
Autores principales: Takyar, Seyedtaghi, Vasavada, Hema, Zhang, Jian-ge, Ahangari, Farida, Niu, Naiqian, Liu, Qing, Lee, Chun Geun, Cohn, Lauren, Elias, Jack A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782056/
https://www.ncbi.nlm.nih.gov/pubmed/24043765
http://dx.doi.org/10.1084/jem.20121200
_version_ 1782285512257568768
author Takyar, Seyedtaghi
Vasavada, Hema
Zhang, Jian-ge
Ahangari, Farida
Niu, Naiqian
Liu, Qing
Lee, Chun Geun
Cohn, Lauren
Elias, Jack A.
author_facet Takyar, Seyedtaghi
Vasavada, Hema
Zhang, Jian-ge
Ahangari, Farida
Niu, Naiqian
Liu, Qing
Lee, Chun Geun
Cohn, Lauren
Elias, Jack A.
author_sort Takyar, Seyedtaghi
collection PubMed
description Asthma, the prototypic Th2-mediated inflammatory disorder of the lung, is an emergent disease worldwide. Vascular endothelial growth factor (VEGF) is a critical regulator of pulmonary Th2 inflammation, but the underlying mechanism and the roles of microRNAs (miRNAs) in this process have not been defined. Here we show that lung-specific overexpression of VEGF decreases miR-1 expression in the lung, most prominently in the endothelium, and a similar down-regulation occurs in lung endothelium in Th2 inflammation models. Intranasal delivery of miR-1 inhibited inflammatory responses to ovalbumin, house dust mite, and IL-13 overexpression. Blocking VEGF inhibited Th2-mediated lung inflammation, and this was restored by antagonizing miR-1. Using mRNA arrays, Argonaute pull-down assays, luciferase expression assays, and mutational analysis, we identified Mpl as a direct target of miR-1 and showed that VEGF controls the expression of endothelial Mpl during Th2 inflammation via the regulation of miR-1. In vivo knockdown of Mpl inhibited Th2 inflammation and indirectly inhibited the expression of P-selectin in lung endothelium. These experiments define a novel VEGF–miR-1–Mpl–P-selectin effector pathway in lung Th2 inflammation and herald the utility of miR-1 and Mpl as potential therapeutic targets for asthma.
format Online
Article
Text
id pubmed-3782056
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-37820562014-03-23 VEGF controls lung Th2 inflammation via the miR-1–Mpl (myeloproliferative leukemia virus oncogene)–P-selectin axis Takyar, Seyedtaghi Vasavada, Hema Zhang, Jian-ge Ahangari, Farida Niu, Naiqian Liu, Qing Lee, Chun Geun Cohn, Lauren Elias, Jack A. J Exp Med Article Asthma, the prototypic Th2-mediated inflammatory disorder of the lung, is an emergent disease worldwide. Vascular endothelial growth factor (VEGF) is a critical regulator of pulmonary Th2 inflammation, but the underlying mechanism and the roles of microRNAs (miRNAs) in this process have not been defined. Here we show that lung-specific overexpression of VEGF decreases miR-1 expression in the lung, most prominently in the endothelium, and a similar down-regulation occurs in lung endothelium in Th2 inflammation models. Intranasal delivery of miR-1 inhibited inflammatory responses to ovalbumin, house dust mite, and IL-13 overexpression. Blocking VEGF inhibited Th2-mediated lung inflammation, and this was restored by antagonizing miR-1. Using mRNA arrays, Argonaute pull-down assays, luciferase expression assays, and mutational analysis, we identified Mpl as a direct target of miR-1 and showed that VEGF controls the expression of endothelial Mpl during Th2 inflammation via the regulation of miR-1. In vivo knockdown of Mpl inhibited Th2 inflammation and indirectly inhibited the expression of P-selectin in lung endothelium. These experiments define a novel VEGF–miR-1–Mpl–P-selectin effector pathway in lung Th2 inflammation and herald the utility of miR-1 and Mpl as potential therapeutic targets for asthma. The Rockefeller University Press 2013-09-23 /pmc/articles/PMC3782056/ /pubmed/24043765 http://dx.doi.org/10.1084/jem.20121200 Text en © 2013 Takyar et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Article
Takyar, Seyedtaghi
Vasavada, Hema
Zhang, Jian-ge
Ahangari, Farida
Niu, Naiqian
Liu, Qing
Lee, Chun Geun
Cohn, Lauren
Elias, Jack A.
VEGF controls lung Th2 inflammation via the miR-1–Mpl (myeloproliferative leukemia virus oncogene)–P-selectin axis
title VEGF controls lung Th2 inflammation via the miR-1–Mpl (myeloproliferative leukemia virus oncogene)–P-selectin axis
title_full VEGF controls lung Th2 inflammation via the miR-1–Mpl (myeloproliferative leukemia virus oncogene)–P-selectin axis
title_fullStr VEGF controls lung Th2 inflammation via the miR-1–Mpl (myeloproliferative leukemia virus oncogene)–P-selectin axis
title_full_unstemmed VEGF controls lung Th2 inflammation via the miR-1–Mpl (myeloproliferative leukemia virus oncogene)–P-selectin axis
title_short VEGF controls lung Th2 inflammation via the miR-1–Mpl (myeloproliferative leukemia virus oncogene)–P-selectin axis
title_sort vegf controls lung th2 inflammation via the mir-1–mpl (myeloproliferative leukemia virus oncogene)–p-selectin axis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782056/
https://www.ncbi.nlm.nih.gov/pubmed/24043765
http://dx.doi.org/10.1084/jem.20121200
work_keys_str_mv AT takyarseyedtaghi vegfcontrolslungth2inflammationviathemir1mplmyeloproliferativeleukemiavirusoncogenepselectinaxis
AT vasavadahema vegfcontrolslungth2inflammationviathemir1mplmyeloproliferativeleukemiavirusoncogenepselectinaxis
AT zhangjiange vegfcontrolslungth2inflammationviathemir1mplmyeloproliferativeleukemiavirusoncogenepselectinaxis
AT ahangarifarida vegfcontrolslungth2inflammationviathemir1mplmyeloproliferativeleukemiavirusoncogenepselectinaxis
AT niunaiqian vegfcontrolslungth2inflammationviathemir1mplmyeloproliferativeleukemiavirusoncogenepselectinaxis
AT liuqing vegfcontrolslungth2inflammationviathemir1mplmyeloproliferativeleukemiavirusoncogenepselectinaxis
AT leechungeun vegfcontrolslungth2inflammationviathemir1mplmyeloproliferativeleukemiavirusoncogenepselectinaxis
AT cohnlauren vegfcontrolslungth2inflammationviathemir1mplmyeloproliferativeleukemiavirusoncogenepselectinaxis
AT eliasjacka vegfcontrolslungth2inflammationviathemir1mplmyeloproliferativeleukemiavirusoncogenepselectinaxis